glp-1 shortages Shortage = Over GLP-1 No Longer on FDA's

Concurrent GH secretagogue and IGF1R agonist research uses compounds like CJC-1295/Ipamorelin alongside IGF-1 LR3 to study whether pulsatile endogenous GH/IGF-1 release combined with sustained IGF1R activation produces additive or synergistic effects on muscle, bone, or other target tissues

Initial Consultation A thorough skin assessment and history review to set your treatment goals

Use a humidifier Helps counteract dryness in air-conditioned rooms or cold weather

Until recently, GLP-1s were only indicated and marketed for the management of type II diabetes

Insurance coverage will be determined after FDA approval